Early-stage gene therapy shows potential against Parkinson’s
An early-stage gene therapy has shown potential for the treatment of Parkinson’s disease in a study published in The Lancet.
The gene-based biopharma, Oxford BioMedica, is behind the research to develop ProSavin. Parkinson’s disease is typically treated with oral dopamine replacement therapies, whereas the investigational gene therapy aims to restore dopamine production.
Gene therapy might offer hope in Parkinson’s (OnMedica).
Oxford BioMedica announces publication of ProSavin phase I/II study in The Lancet (BioMedica press release).
Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.